BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

789 related articles for article (PubMed ID: 31627733)

  • 1. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.
    Keenan BP; Fong L; Kelley RK
    J Immunother Cancer; 2019 Oct; 7(1):267. PubMed ID: 31627733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer.
    O'Rourke JM; Sagar VM; Shah T; Shetty S
    World J Gastroenterol; 2018 Oct; 24(39):4436-4447. PubMed ID: 30357021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for hepatocellular carcinoma.
    Li S; Yang F; Ren X
    Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications.
    Hou J; Zhang H; Sun B; Karin M
    J Hepatol; 2020 Jan; 72(1):167-182. PubMed ID: 31449859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes.
    Cao D; Chen MK; Zhang QF; Zhou YF; Zhang MY; Mai SJ; Zhang YJ; Chen MS; Li XX; Wang HY
    Aging (Albany NY); 2020 Jun; 12(12):12187-12205. PubMed ID: 32544882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives.
    Roth GS; Decaens T
    Eur J Cancer; 2017 Dec; 87():101-112. PubMed ID: 29145036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autophagy in the "inflammation-carcinogenesis" pathway of liver and HCC immunotherapy.
    Yu S; Wang Y; Jing L; Claret FX; Li Q; Tian T; Liang X; Ruan Z; Jiang L; Yao Y; Nan K; Lv Y; Guo H
    Cancer Lett; 2017 Dec; 411():82-89. PubMed ID: 28987386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
    Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
    Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
    Mukaida N; Nakamoto Y
    World J Gastroenterol; 2018 May; 24(17):1839-1858. PubMed ID: 29740200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells.
    Ruf B; Heinrich B; Greten TF
    Cell Mol Immunol; 2021 Jan; 18(1):112-127. PubMed ID: 33235387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of Hepatocellular Carcinoma.
    Heinrich B; Czauderna C; Marquardt JU
    Oncol Res Treat; 2018; 41(5):292-297. PubMed ID: 29705790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies.
    Giraud J; Chalopin D; Blanc JF; Saleh M
    Front Immunol; 2021; 12():655697. PubMed ID: 33815418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors for hepatocellular carcinoma.
    El Dika I; Khalil DN; Abou-Alfa GK
    Cancer; 2019 Oct; 125(19):3312-3319. PubMed ID: 31290997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?
    Obeid JM; Kunk PR; Zaydfudim VM; Bullock TN; Slingluff CL; Rahma OE
    Cancer Immunol Immunother; 2018 Feb; 67(2):161-174. PubMed ID: 29052780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.
    Dai X; Guo Y; Hu Y; Bao X; Zhu X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Fang W
    Theranostics; 2021; 11(7):3489-3501. PubMed ID: 33537099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma.
    Montella L; Sarno F; Ambrosino A; Facchini S; D'Antò M; Laterza MM; Fasano M; Quarata E; Ranucci RAN; Altucci L; Berretta M; Facchini G
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
    Zhang Q; Lou Y; Bai XL; Liang TB
    World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.